SCHEMBL4246629

SCHEMBL4246629

COc1ccc2c(=O)n(NCc3ccc(F)cc3F)c(-c3ccc(F)cc3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.54
MAPT P10636 3/20 0.54
ALDH1A1 P00352 7/20 0.53
MDM2 Q00987 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
F2RL1 P55085 1/20 0.49
HPGD P15428 2/20 0.48
LMNA P02545 5/20 0.47
HTT P42858 2/20 0.47
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
APOBEC3G Q9HC16 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
AKR1B10 O60218 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238641 0.83 NPSR1 (0.61) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4237523 0.83 CYP3A4 (0.51) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4237530 0.83 SMN1; SMN2 (0.73) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4241958 0.82 MAPT (0.49) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4236257 0.80 ALDH1A1 (0.70) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL1463978 0.76 KCNH2 (0.60) NPSR1MAPTALDH1A1F2RL1HPGD
SCHEMBL4237239 0.76 SMN1; SMN2 (0.61) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4240089 0.75 ALDH1A1 (0.56) NPSR1MAPTALDH1A1MDM2SMN1; SMN2
SCHEMBL4233295 0.73 SMN1; SMN2 (0.53) NPSR1MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL4238065 0.72 ALDH1A1 (0.65) NPSR1MAPTALDH1A1MDM2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 NPSR1 981/4885MAPT 4430/4885ALDH1A1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.